Kailera
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
Kailera Therapeutics, Jamie Coleman, Chief Commercial Officer, Obesity Treatment, Zepbound, Eli Lilly
Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics
Kailera Secures $400M Funding to Advance China-Developed Obesity and Diabetes Therapies
Kailera, obesity, diabetes, China-developed drugs, $400M funding, pharmaceuticals, biotech